We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Akili

News List

Akili, Shionogi to develop digital therapeutics in key Asian markets biospectrumasia
March 11, 2019
Akili Interactive and Shionogi & Co. have announced that they have entered into a strategic partnership for the commercialization of Akili’s digital medicines, AKL-T01 and AKL-T02, in Japan and Taiwan, China region in China.
Akili raises extra $13M ahead of FDA decision on prescription videogame for ADHD fiercebiotech
August 10, 2018
Akili Interactive has gathered an additional $13 million to fund its prescription videogame treatments, bringing its series C total up to $68 million. Meanwhile, it is awaiting an FDA clearance decision on its recently filed digital therapeutic for pediat
Akili's video game digital treatment shows promise in ADHD, eyes FDA approval pharmafile
December 05, 2017
Akili, an unlisted affiliate of London-listed PureTech Health, has unveiled top-line results of AKL-T01, a novel digital medicine which takes the form of a video game, in the treatment of paediatric attention deficit hyperactivity disorder (ADHD).